Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 18,280 results that match your search.18,280 results
  • On November 29 2000, a majority of the United States Court of Appeals for the Federal Circuit, sitting en banc, rendered an opinion in Festo Corp v Shoketsu Kogyo Kabushiki Co, published at 56 USPQ 2d 1865, which effectively extinguishes the application of the doctrine of equivalents to any term of a patent claim that was narrowed by amendment during its prosecution before the US Patent and Trademark Office (USPTO). While the majority opinion does purportedly limit the prosecution estoppel created by amendments that narrow a claim in any respect to those amendments made for reasons "related to patentability" , that opinion is also unequivocally clear in holding that any narrowing amendment to a claim term made for "any reason affecting the issuance of a patent" (56 USPQ 2d at 1870-1871) is "related to patentability" whether made voluntarily or in response to a rejection. Specific mention is made of amendments made for reasons based on 35 USC § § 101 and 112, as well as for prior art reasons based on 35 USC § § 102 and 103 as giving rise to prosecution estoppels and thus foreclosing application of the doctrine of equivalents to amended terms or expressions in claims. The majority opinion leaves an apparent escape hatch from estoppel for narrowing claim amendments made for reasons other than patentability, provided each such reason is stated in the prosecution record at the time of the narrowing amendment but this is of very little practical effect because reasons for narrowing amendments to claims that do not somehow implicate patentability are extremely hard to conceive of, much less substantiate. The majority opinion is explicit in holding that: "When a claim amendment creates prosecution history estoppel with regard to a claim element, there is no range of equivalents available for the amended claim element. Application of the doctrine of equivalents to the claim element is completely barred" (56USPQ2d at 1872).
  • Kay-Uwe Jonas and Martin Viefhues, of Linklaters Oppenhoff & Rädler in Cologne, outline the advantages of filing Madrid Protocol applications in Germany
  • In the second of three articles on IP value issues, Tony Samuel and Graeme Berry query why organizations do not insure their most valuable asset, intellectual property.
  • It is widely believed that change is as good as a rest. Certainly this seems to be the case in the Asia-Pacific, although unfortunately, little has changed and no one has had any rest. The internet dominated the Asian-Pacific scene in last year's survey and its impact is still reverberating through IP practices. If anything it is registering even higher on the Richter scale. Intellectual property lawyers have never been so busy.
  • In the same month that Pfizer scientists from the company´ s laboratories in England received the French Prix Galien award for their discovery and development of Viagra, the drugs company has lost a crucial patent protecting the $332 million drug, clearing the way for rival treatments.
  • John P Fry and Christopher B Roblyer examine how to defend against charges of wilful infringement and the risk of waiving the attorney-client privilege in US patent and trade mark disputes
  • Counterfeit fear over new legislation
  • Shirley Kwok, of Vivien Chan & Co in Hong Kong and Beijing, explains that China has made important progress in tackling domain name disputes in the past year
  • In Mexico, the Domain Name Registrar is an entity called NIC-Mexico (Network Information Centre de Mexico), which handles registration and administration of domain names identified with the ccTLD (country code Top Level Domain) ".mx". NIC-Mexico is not an authority and it has not been granted official authorization for being in charge of the Mexican domain names management. However, NIC-Mexico is today the only "entity" which has responsibility for managing Mexican domains.
  • First you lose $20 million. Then you get it back. Then you lose it again. That is the scenario facing an Indianapolis company, Biomet, which makes orthopedic products.